184 related articles for article (PubMed ID: 25900253)
21. Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria.
Rhee H; Kim MJ; Park YN; Choi JS; Kim KS
J Magn Reson Imaging; 2012 Feb; 35(2):393-8. PubMed ID: 21990116
[TBL] [Abstract][Full Text] [Related]
22. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
23. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
Kim HY; Choi JY; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE; You YK; Kim DG; Jung ES
Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
[TBL] [Abstract][Full Text] [Related]
24. Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma.
An C; Rhee H; Han K; Choi JY; Park YN; Park MS; Kim MJ; Park S
Eur Radiol; 2017 Jun; 27(6):2610-2618. PubMed ID: 27770230
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
26. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
27. MR features of regenerative nodules and dysplastic nodules in the cirrhotic liver.
Xu H; Kong X; Xiong Y; Zhang X
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(5):601-3. PubMed ID: 16463687
[TBL] [Abstract][Full Text] [Related]
28. [The dynamic magnetic resonance study of focal liver lesions by FLASH sequences with bolus intravenous gadolinium-DTPA].
Olivetti L; Grazioli L; Maroldi R; Matricardi L; Milanesio L
Radiol Med; 1992 Apr; 83(4):353-60. PubMed ID: 1318558
[TBL] [Abstract][Full Text] [Related]
29. Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging.
Akai H; Matsuda I; Kiryu S; Tajima T; Takao H; Watanabe Y; Imamura H; Kokudo N; Akahane M; Ohtomo K
Eur J Radiol; 2012 Nov; 81(11):2973-7. PubMed ID: 22280873
[TBL] [Abstract][Full Text] [Related]
30. Intrahepatic distant recurrence after radiofrequency ablation for hepatocellular carcinoma: precursor nodules on pre-procedural gadoxetic acid-enhanced liver magnetic resonance imaging.
Song KD; Rhim H; Lee MW; Kim YS; Kang TW
Acta Radiol; 2017 Jul; 58(7):778-785. PubMed ID: 27903759
[TBL] [Abstract][Full Text] [Related]
31. [The magnetic resonance and histological correlations in hepatocellular carcinoma].
Bartolozzi C; Lencioni R; Caramella D; Paolicchi A; Russo R; Romani R
Radiol Med; 1994; 87(1-2):90-5. PubMed ID: 8128039
[TBL] [Abstract][Full Text] [Related]
32. Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade.
Haimerl M; Utpatel K; Götz A; Zeman F; Fellner C; Nickel D; Luerken L; Brennfleck F; Stroszczynski C; Scheiter A; Verloh N
Sci Rep; 2021 Nov; 11(1):22991. PubMed ID: 34837039
[TBL] [Abstract][Full Text] [Related]
33. Detectability of hepatocellular carcinoma by gadoxetate disodium-enhanced hepatic MRI: tumor-by-tumor analysis in explant livers.
Nakamura Y; Tashiro H; Nambu J; Ohdan H; Kakizawa H; Date S; Awai K
J Magn Reson Imaging; 2013 Mar; 37(3):684-91. PubMed ID: 23055436
[TBL] [Abstract][Full Text] [Related]
34. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
Jang KM; Kim SH; Kim YK; Choi D
Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
[TBL] [Abstract][Full Text] [Related]
35. Texture analysis of MR images to identify the differentiated degree in hepatocellular carcinoma: a retrospective study.
Feng M; Zhang M; Liu Y; Jiang N; Meng Q; Wang J; Yao Z; Gan W; Dai H
BMC Cancer; 2020 Jun; 20(1):611. PubMed ID: 32605628
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.
Alaboudy A; Inoue T; Hatanaka K; Chung H; Hyodo T; Kumano S; Murakami T; Moustafa EF; Kudo M
Oncology; 2011; 81 Suppl 1():66-72. PubMed ID: 22212939
[TBL] [Abstract][Full Text] [Related]
37. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.
Goshima S; Kanematsu M; Watanabe H; Kondo H; Mizuno N; Kawada H; Shiratori Y; Onozuka M; Moriyama N; Bae KT
Eur J Radiol; 2011 Aug; 79(2):e108-12. PubMed ID: 21592707
[TBL] [Abstract][Full Text] [Related]
38. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla.
Park HS; Lee JM; Kim SH; Chang S; Kim SJ; Han JK; Choi BI
J Magn Reson Imaging; 2009 Feb; 29(2):328-35. PubMed ID: 19161184
[TBL] [Abstract][Full Text] [Related]
39. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.
Motosugi U; Bannas P; Sano K; Reeder SB
J Magn Reson Imaging; 2015 Feb; 41(2):251-65. PubMed ID: 25104398
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of combined Gd-EOB-DTPA and gadobutrol magnetic resonance imaging for the prediction of hepatocellular carcinoma grading.
Schelhorn J; Best J; Dechêne A; Göbel T; Bertram S; Lauenstein T; Kinner S
Acta Radiol; 2016 Aug; 57(8):932-8. PubMed ID: 26586852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
